Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Erlotinib

Erlotinib ▴ Erlotinib is an orally administered quinazoline derivative that targets and inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase enzyme, thereby disrupting signalling pathways that encourage cell growth and inhibit apoptosis. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

Loading next page...
 
/lp/springer-journals/erlotinib-5xnUVbLiQG
Publisher
Springer Journals
Copyright
Copyright © 2006 by Adis Data Information BV
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200605010-00005
Publisher site
See Article on Publisher Site

Abstract

▴ Erlotinib is an orally administered quinazoline derivative that targets and inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase enzyme, thereby disrupting signalling pathways that encourage cell growth and inhibit apoptosis.

Journal

American Journal of CancerSpringer Journals

Published: Aug 10, 2012

References